Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.

[1]  G. Moneta,et al.  Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study) , 2007 .

[2]  M. Hennerici,et al.  High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.

[3]  G. Watts.  You need hands , 2006, The Lancet.

[4]  J. Liao.  Clinical implications for statin pleiotropy , 2005, Current opinion in lipidology.

[5]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[6]  A. Algra,et al.  Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study , 2005, The Lancet.

[7]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[8]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[9]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[10]  D. Waters,et al.  Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? , 2004, The American journal of cardiology.

[11]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[12]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[13]  R. de Caterina,et al.  Statins and stroke: evidence for cholesterol-independent effects , 2002 .

[14]  M. Ezekowitz,et al.  Effects of Atorvastatin on Stroke in Patients With Unstable Angina or Non-Q-Wave Myocardial Infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Substudy , 2002, Circulation.

[15]  K. Mann,et al.  Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation , 2001, Circulation.

[16]  P. Shah,et al.  Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization , 2001, Circulation.

[17]  P Glasziou,et al.  Pravastatin therapy and the risk of stroke. , 2000, The New England journal of medicine.

[18]  A. Brett.  Pravastatin therapy and the risk of stroke. , 2000, The New England journal of medicine.

[19]  N. Delanty,et al.  Neuroprotective properties of statins in cerebral ischemia and stroke. , 1999, Stroke.

[20]  B. Davis,et al.  Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. , 1999, Circulation.

[21]  K. Iseki,et al.  Low serum cholesterol as a risk factor for hemorrhagic stroke in men: a community-based mass screening in Okinawa, Japan. , 1999, Japanese circulation journal.

[22]  D. Jacobs,et al.  Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program. , 1996, Stroke.

[23]  D. Kromhout.  Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.

[24]  D. Waters,et al.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.

[25]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[26]  C. Furberg,et al.  Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.

[27]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[28]  Katsuhiko Yano,et al.  Elevated Serum Cholesterol Is a Risk Factor for Both Coronary Heart Disease and Thromboembolic Stroke in Hawaiian Japanese Men: Implications of Shared Risk , 1994, Stroke.

[29]  David C. Atkins,et al.  Cholesterol Reduction and the Risk for Stroke in Men , 1993, Annals of Internal Medicine.

[30]  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. , 1991, JAMA.

[31]  D. Jacobs,et al.  Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.

[32]  K. Yano,et al.  Dietary and other risk factors for stroke in Hawaiian Japanese men. , 1985, Stroke.